Soluble HLA in saliva of patients with autoimmune rheumatic diseases

Adamashvili, Irena; Pressly, Thomas A.; Gebel, Howard M.; Milford, Edgar L.; Wolf, Robert; Mancini, Mary C.; Sittg, Kevin; Ghali, G.E.; Hall, Vicky; McDonald, John C.

doi:10.1007/s00296-002-0173-3

Cited by 8 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the serum level of sHLA-I is significantly elevated in patients with various inflammatory diseases [5-8] although this is not necessarily the case for serum sHLA-II levels [9,10]. Preliminary evidence suggests that patients with systemic lupus erythematosus (SLE) are at increased risk of developing active disease in the presence of high sHLA-I levels in the saliva, while sHLA-II level has not been observed to be elevated in rheumatological diseases [11]. Typically, sHLA-I exists in very low quantities in the saliva, sweat, urine and/or tears of normal individuals, while sHLA-II is routinely detectable in all these body fluids [1].…”

Section: Introductionmentioning

confidence: 99%

Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study

Minagar

Adamashvili

Kelley

et al. 2007

J Neuroinflammation

Self Cite

View full text Add to dashboard Cite

Objective: Potential surrogate markers of disease activity, including response to therapy, are particularly important in a neurological disorder such as multiple sclerosis (MS) which often has a fluctuating course. Based upon previous studies in our laboratory, we hypothesized that measurement of soluble HLA (sHLA) molecules class II in saliva of MS patients can serve as marker of therapeutic response to high dose interferon beta-1a. Methods:We measured the expression patterns of sHLA-II in saliva in 17 patients with relapsing/ remitting MS and compared the results to clinical course and brain MRI. For comparison purposes we also assayed the saliva sHLA-II levels in 53 normal control subjects. Solid phase ELISA was used for measurement of sHLA-I and sHLA-II concentrations at baseline and after three and six months of treatment with high dose interferon beta-1a (IFN β-1a). Results:The mean saliva sHLA-ll levels in MS patients was significantly higher than normal controls (354 ± 42 unit/mL vs. 222 ± 18 unit/mL, t= 8.16, p < 0.003). Comparison of saliva sHLA-II values before and after treatment with IFN β-1a revealed a consistent increase in mean concentration. The increase in saliva sHLA-II values (354 ± 42 unit/mL at baseline versus 821 ± 86 unit/mL at 3 months and 776 ± 63 unit/mL at 6 months, in unit/mL, p < 0.001 for both comparisons) was associated with a stable clinical course and a decline of the number of contrast-enhancing lesions on brain MRI. Comparison of the volume of T2-weighted lesions and the number of black holes on T1-weighted images did not reveal any significant changes (during pre-treatment versus posttreatment month 6) or any correlations with saliva sHLA-II levels. Saliva sHLA-I levels were not detectable. Conclusion:Serial measurement of saliva sHLA-II may serve as a potential marker of therapeutic response to IFN β-1a. Larger clinical studies involving more RRMS patients over longer periods of time are needed to further test the significance and value of saliva sHLA-II as an accurate marker of therapeutic response to beta-interferons.

show abstract

Section: Introductionmentioning

confidence: 99%

Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study

Minagar

Adamashvili

Kelley

et al. 2007

J Neuroinflammation

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, excretion of sHLA-I in sweat has been found to be in markedly lower quantities than in serum [11,38]. We reported the occurrence of 39 kDa sHLA-I in saliva as well as in serum during active Sjögren's disease and systemic lupus erythematosus, and the presence of 35–37 kDa HLA-I in both body fluids when the disease was relatively inactive [10,35]. Taken together, it appears that the presence of sHLA in different body fluids has physiological relevance.…”

Section: Discussionmentioning

confidence: 99%

“…We reported a substantial elevation of saliva sHLA-I in patients with autoimmune rheumatic diseases, when the saliva sHLA-II concentrations were in normal range [10]. sHLA-I concentrations in saliva were observed to be related to the activity or clinical course of rheumatological diseases.…”

Section: Discussionmentioning

confidence: 99%

“…The solid-phase ELISA for sHLA-I has been previously described [3,10,16,21]. The levels of sHLA-II were determined using a previously described assay [9,11] with minor modifications.…”

Section: Methodsmentioning

confidence: 99%

“…sHLA-I was either non-detectable, or present in very low quantities, in the urine, sweat, saliva and tears of normal individuals. sHLA-I is highly elevated in the saliva of patients with autoimmune rheumatic diseases [2,10]. sHLA-II is routinely detectable in the urine, tears, sweat and saliva of normal individuals, but concentrations of sHLA-II are not observed to be elevated in rheumatological diseases [10,11].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations